603717.SH
天域生物
SSE · Industrials · Engineering & Construction · CN
CNY 6.31
−0.63%Year over year
Reported trailing growth
- Revenue
- -19.8%
- EBITDA
- —
- EBIT
- -63.1%
- EPS
- -28.0%
- Free cash flow
- -14.6%
- Operating cash flow
- -13.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.4%
- EBITDA
- -16.1%
- EBIT
- -13.6%
- Net income
- +0.4%
- EPS
- +0.4%
- Free cash flow
- +109.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026